GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Cash Flow from Operations

Bicycle Therapeutics (Bicycle Therapeutics) Cash Flow from Operations : $-85.09 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, Bicycle Therapeutics's Net Income From Continuing Operations was $-26.56 Mil. Its Depreciation, Depletion and Amortization was $1.66 Mil. Its Change In Working Capital was $-54.58 Mil. Its cash flow from deferred tax was $-0.77 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $9.28 Mil. And its Cash Flow from Others was $0.11 Mil. In all, Bicycle Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2024 was $-70.87 Mil.


Bicycle Therapeutics Cash Flow from Operations Historical Data

The historical data trend for Bicycle Therapeutics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics Cash Flow from Operations Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial -28.61 -17.79 -14.79 -86.11 -60.63

Bicycle Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.41 34.10 -1.03 -47.29 -70.87

Bicycle Therapeutics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Bicycle Therapeutics's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Bicycle Therapeutics's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-85.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bicycle Therapeutics  (NAS:BCYC) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Bicycle Therapeutics's net income from continuing operations for the three months ended in Mar. 2024 was $-26.56 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Bicycle Therapeutics's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $1.66 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Bicycle Therapeutics's change in working capital for the three months ended in Mar. 2024 was $-54.58 Mil. It means Bicycle Therapeutics's working capital declined by $54.58 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Bicycle Therapeutics's cash flow from deferred tax for the three months ended in Mar. 2024 was $-0.77 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Bicycle Therapeutics's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Bicycle Therapeutics's asset impairment charge for the three months ended in Mar. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Bicycle Therapeutics's stock based compensation for the three months ended in Mar. 2024 was $9.28 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Bicycle Therapeutics's cash flow from others for the three months ended in Mar. 2024 was $0.11 Mil.


Bicycle Therapeutics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicycle Therapeutics (Bicycle Therapeutics) Business Description

Traded in Other Exchanges
Address
Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Executives
Nigel Crockett officer: Chief Business Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Travis Alvin Thompson officer: Chief Accounting Officer C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Alistair Milnes officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee director, officer: Chief Executive Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Nicholas Keen officer: Chief Scientific Officer C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Michael Skynner officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Lee Kalowski officer: President and CFO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Santiago Arroyo officer: Chief Development Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Dominic Smethurst officer: Chief Medical Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham director 1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098

Bicycle Therapeutics (Bicycle Therapeutics) Headlines

From GuruFocus

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 02-28-2023